Clinical Trial

Predictors of HCC in Post-HCV Cirrhotic Patients After SVR

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Trial Details
NCT Number NCT07097870
Lead Sponsor Sohag University
Conditions HCC - Hepatocellular Carcinoma
Enrollment 400 participants
Start Date 2025-08
Primary Completion 2025-09 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-05